C. Bang

Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months

N. Talley, B. Moum, K. Lauritsen, 2001, Alimentary pharmacology & therapeutics.

Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin

O. Dalgard, H. Midgard, N. Raknerud, 2010, Scandinavian journal of gastroenterology.

Incidence rates and causes of cirrhosis in a Norwegian population

Z. Konopski, K. Bjøro, J. W. Haukeland, 2007, Scandinavian journal of gastroenterology.

Esomeprazole 20mg maintains symptom control in endoscopy-negative GERD: A randomized placebo-controlled trial of on-demand therapy for 6 months

N. Talley, B. Moum, T. Schulz, 2000 .

ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis

S. Frigstad, Z. Konopski, J. W. Haukeland, 2008, Scandinavian journal of gastroenterology.

A double‐blind, placebo‐controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

I. Holme, L. Elsborg, H. Nyhlin, 2004, Scandinavian journal of gastroenterology.

Randomised clinical trial: a comparison between a GerdQ‐based algorithm and an endoscopy‐based approach for the diagnosis and initial treatment of GERD

B. Moum, J. Hatlebakk, C. Jonasson, 2012, Alimentary pharmacology & therapeutics.

Tegaserod is an effective and safe therapy for irritable bowel syndrome in a nordic population

I. Holme, L. Elsborg, H. Nyhlin, 2003 .